Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites

References

• Abe K, Inoue O, Yumioka E. (1990). Biliary excretion of metabolites of baicalin and baicalein in rats. Chem Pharm Bull 38:209–11
   PubMed Web of Science ®Google Scholar
• Akamine Y, Miura M, Komori H, et al. (2015). The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion. Drug Metab Pharmacokinet 30:352–7
   PubMed Web of Science ®Google Scholar
• Ammon HP, Wahl MA. (1991). Pharmacology of Curcuma longa. Planta Medica 57:1–7
   PubMed Web of Science ®Google Scholar
• Asai A, Miyazawa T. (2000). Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci 67:2785–93
   PubMed Web of Science ®Google Scholar
• Basu NK, Kole L, Kubota S, Owens IS. (2004). Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32:768–73
   PubMed Web of Science ®Google Scholar
• Basu S, Jana S, Patel VB, Patel H. (2013). Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res 27:1548–56
   PubMed Web of Science ®Google Scholar
• Boxenbaum H. (1999). Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47–52
   PubMed Web of Science ®Google Scholar
• Cao Y, Xu RX, Liu Z. (2014). A high-throughput quantification method of curcuminoids and curcumin metabolites in human plasma via high-performance liquid chromatography/tandem mass spectrometry. J Chromatogr B 949:70–8
   PubMed Web of Science ®Google Scholar
• CDER. (2012). Drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
   Google Scholar
• Che CT, Wang ZJ, Chow MS, Lam CW. (2013). Herb–herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules 18:5125–41
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Z, Huang Y, et al. (2014). Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid Based Complement Alternat Med 2014:168940
   PubMedGoogle Scholar
• Chen W, Fan-Havard P, Yee LD, et al. (2012). A liquid chromatography-tandem mass spectrometric method for quantification of curcumin-O-glucuronide and curcumin in human plasma. J. Chromatogr B Analyt Technol Biomed Life Sci 900:89–93
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, Kim RB. (2012). Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 52:249–73
   PubMed Web of Science ®Google Scholar
• Dhillon N, Aggarwal BB, Newman RA, et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491–9
   PubMed Web of Science ®Google Scholar
• Dresser GK, Kim RB, Bailey DG. (2005). Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77:170–7
   PubMed Web of Science ®Google Scholar
• Gao C, Chen X, Zhong D. (2011). Absorption and disposition of scutellarin in rats: a pharmacokinetic explanation for the high exposure of its isomeric metabolite. Drug Metab Dispos 39:2034–44
   PubMed Web of Science ®Google Scholar
• Gao C, Zhang H, Guo Z, et al. (2012). Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos 40:2009–20
   PubMed Web of Science ®Google Scholar
• Hoehle SI, Pfeiffer E, Metzler M. (2007). Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases. Mol Nutr Food Res 51:932–8
   PubMed Web of Science ®Google Scholar
• Holder GM, Plummer JL, Ryan AJ. (1978). The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 8:761–8
   PubMed Web of Science ®Google Scholar
• Honig PK, Wortham DC, Zamani K, et al. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269:1513–18
   PubMed Web of Science ®Google Scholar
• International Transporter Consortium, Giacomini KM, Huang SM, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36
   PubMed Web of Science ®Google Scholar
• Ireson CR, Jones DJL, Orr S, et al. (2002). Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 11:105–11
   PubMed Web of Science ®Google Scholar
• Johne A, Brockmoller J, Bauer S, et al. (1999). Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66:338–45
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014–23
   PubMed Web of Science ®Google Scholar
• Lee JH, Shin YJ, Kim HJ, et al. (2011). Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. Int J Pharm 410:68–74
   PubMed Web of Science ®Google Scholar
• Metzler M, Pfeiffer E, Schulz SI, Dempe JS. (2013). Curcumin uptake and metabolism. BioFactors 39:14–20
   PubMed Web of Science ®Google Scholar
• Nezasa K, Takao A, Kimura K, et al. (2002). Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715–27
   PubMed Web of Science ®Google Scholar
• Pan MH, Huang TM, Lin JK. (1999). Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486–94
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Welden N, et al. (2002). The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34:234–8
   PubMed Web of Science ®Google Scholar
• Ravindranath V, Chandrasekhara N. (1981). Metabolism of curcumin – studies with 3H curcumin. Toxicology 22:337–44
   PubMed Web of Science ®Google Scholar
• Sheng J, Tian X, Xu G, et al. (2015). The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism. Drug Metab Dispos 43:63–72
   PubMed Web of Science ®Google Scholar
• Shukla S, Zaher H, Hartz A, et al. (2009). Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26:480–7
   PubMed Web of Science ®Google Scholar
• Sreenivasan S, Krishnakumar S. (2015). Synergistic effect of curcumin in combination with anticancer agents in human retinoblastoma cancer cells lines. Curr Eye Res 40:1153–65
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Sugiura T, Umeda S, et al. (2011). Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos 39:1088–96
   PubMed Web of Science ®Google Scholar
• Tindle HA, Davis RB, Phillips RS, Eisenberg DM. (2005). Trends in use of complementary and alternative medicine by us adults: 1997–2002. Altern Ther Health Med 11:42–9
   PubMed Web of Science ®Google Scholar
• Volak LP, Ghirmai S, Cashman JR, Court MH. (2008). Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 36:1594–605
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Duan SX, et al. (1994). In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 34:1222–7
   PubMed Web of Science ®Google Scholar
• Wang C, Wang C, Liu Q, et al. (2014). Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos 42:996–1007
   PubMed Web of Science ®Google Scholar
• Wang K, Qiu F. (2013). Curcuminoid metabolism and its contribution to the pharmacological effects. Curr Drug Metab 14:791–806
   PubMed Web of Science ®Google Scholar
• Wortelboer HM, Usta M, van der Velde AE, et al. (2003). Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin. Chem Res Toxicol 16:1642–51
   PubMed Web of Science ®Google Scholar
• Xing J, Chen X, Zhong D. (2005). Absorption and enterohepatic circulation of baicalin in rats. Life Sci 78:140–6
   PubMed Web of Science ®Google Scholar
• Zhang W, Tan TM, Lim LY. (2007). Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110–15
   PubMed Web of Science ®Google Scholar
• Zhong K, Li X, Xie C, et al. (2014). Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. Antimicrob Agents Chemother 58:4153–61
   PubMed Web of Science ®Google Scholar
• Zhou X, Gao ZW, Meng J, et al. (2013). Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs. Acta Pharmacol Sin 34:1420–6
   PubMed Web of Science ®Google Scholar
• Zhu Y, Meng Q, Wang C, et al. (2014). Methotrexate-bestatin interaction: involvement of P-glycoprotein and organic anion transporters in rats. Int J Pharm 465:368–77
   PubMed Web of Science ®Google Scholar